Qurient Co. Ltd Net Assets
Qurient Co. Ltd net assets. Based on the latest financial reports, Qurient Co. Ltd (115180) has net assets worth ₩21.80 Billion KRW (≈ $14.78 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩45.56 Billion ≈ $30.88 Million USD) and total liabilities (₩23.76 Billion ≈ $16.10 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Qurient Co. Ltd (115180) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩21.80 Billion |
| % of Total Assets | 47.85% |
| Annual Growth Rate | N/A |
| 5-Year Change | -27.53% |
| 10-Year Change | 60.96% |
| Growth Volatility | 230.86 |
Net Assets of Qurient Co. Ltd (2014–2025)
Net assets of Qurient Co. Ltd from 2014 to 2025. This chart illustrates how Qurient Co. Ltd's net assets have evolved over time, based on quarterly financial data. See net asset quality index of Qurient Co. Ltd to measure how much of total assets are equity-financed.
Annual Net Assets for Qurient Co. Ltd (2014–2025)
The table below shows the annual net assets of Qurient Co. Ltd from 2014 to 2025. For live market cap and overall valuation, see market cap of Qurient Co. Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩39.19 Billion ≈ $26.56 Million |
-31.96% |
| 2024-12-31 | ₩57.60 Billion ≈ $39.03 Million |
+23.55% |
| 2023-12-31 | ₩46.62 Billion ≈ $31.59 Million |
+32.68% |
| 2022-12-31 | ₩35.14 Billion ≈ $23.81 Million |
-35.02% |
| 2021-12-31 | ₩54.08 Billion ≈ $36.65 Million |
-4.40% |
| 2020-12-31 | ₩56.57 Billion ≈ $38.33 Million |
+225.50% |
| 2019-12-31 | ₩17.38 Billion ≈ $11.78 Million |
-55.90% |
| 2018-12-31 | ₩39.41 Billion ≈ $26.70 Million |
+171.15% |
| 2017-12-31 | ₩14.53 Billion ≈ $9.85 Million |
-40.31% |
| 2016-12-31 | ₩24.35 Billion ≈ $16.50 Million |
+741.35% |
| 2015-12-31 | ₩2.89 Billion ≈ $1.96 Million |
+113.35% |
| 2014-12-31 | ₩-21.68 Billion ≈ $-14.69 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Qurient Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21557472987000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Qurient Co. Ltd Net Assets Breakdown (December 2025)
Qurient Co. Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩271.91 Billion | 798.73% |
| Total Equity | ₩34.04 Billion | 100.00% |
Qurient Co. Ltd Competitors by Market Cap
The table below lists competitors of Qurient Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
First Tractor Company Limited
F:FTP
|
$410.11 Million |
|
Jiangyin Pivot Automotive Products Co. Ltd.
SHE:301181
|
$410.34 Million |
|
Cheryong Electric Co.Ltd
KQ:033100
|
$410.37 Million |
|
Zhejiang Jinlihua Electric Co
SHE:300069
|
$410.73 Million |
|
Yonker Environmental Protect
SHE:300187
|
$410.02 Million |
|
Qingdao Huijintong Power
SHG:603577
|
$409.92 Million |
|
Hi-Trend Tech(Shanghai)Co Ltd
SHG:688391
|
$409.91 Million |
|
Jiangsu WELLE Environmental Co Ltd
SHE:300190
|
$409.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Qurient Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 57,598,039,950 to 34,042,395,360, a change of -23,555,644,590 (-40.9%).
- Net loss of 30,053,954,230 reduced equity.
- Dividend payments of 69,410,110 reduced retained earnings.
- New share issuances of 21,231,379,650 increased equity.
- Other factors decreased equity by 14,663,659,900.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-30.05 Billion | -88.28% |
| Dividends Paid | ₩69.41 Million | -0.2% |
| Share Issuances | ₩21.23 Billion | +62.37% |
| Other Changes | ₩-14.66 Billion | -43.07% |
| Total Change | ₩- | -40.90% |
Book Value vs Market Value Analysis
This analysis compares Qurient Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 17.74x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 4.21x to 17.74x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | ₩3856.41 | ₩16240.00 | x |
| 2022-12-31 | ₩1689.35 | ₩16240.00 | x |
| 2023-12-31 | ₩1754.95 | ₩16240.00 | x |
| 2024-12-31 | ₩1783.92 | ₩16240.00 | x |
| 2025-12-31 | ₩915.45 | ₩16240.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Qurient Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -88.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -430.41%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 1.82x
- Recent ROE (-88.28%) is below the historical average (-79.85%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | -4973.15% | 0.02x | 0.00x | ₩-8.54 Billion |
| 2015 | -321.43% | 0.00% | 0.00x | 1.33x | ₩-9.59 Billion |
| 2016 | -43.27% | 0.00% | 0.00x | 1.08x | ₩-12.97 Billion |
| 2017 | -83.92% | 0.00% | 0.00x | 1.08x | ₩-13.65 Billion |
| 2018 | -41.66% | 0.00% | 0.00x | 1.10x | ₩-20.36 Billion |
| 2019 | -130.61% | 0.00% | 0.00x | 1.18x | ₩-24.44 Billion |
| 2020 | -36.24% | 0.00% | 0.00x | 1.08x | ₩-26.15 Billion |
| 2021 | -44.28% | -467.63% | 0.08x | 1.12x | ₩-28.01 Billion |
| 2022 | -82.24% | -300.61% | 0.22x | 1.24x | ₩-28.55 Billion |
| 2023 | -45.30% | -233.80% | 0.17x | 1.13x | ₩-25.78 Billion |
| 2024 | -40.92% | -256.73% | 0.14x | 1.14x | ₩-29.33 Billion |
| 2025 | -88.28% | -430.41% | 0.11x | 1.82x | ₩-33.46 Billion |
Industry Comparison
This section compares Qurient Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $417,529,273,243
- Average return on equity (ROE) among peers: -6.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Qurient Co. Ltd (115180) | ₩21.80 Billion | 0.00% | 1.09x | $410.10 Million |
| ORIENTBIO Inc. (002630) | $97.94 Billion | -19.53% | 0.76x | $96.19 Million |
| Green Cross (005250) | $1.97 Trillion | 1.67% | 0.83x | $290.81 Million |
| Green Cross Holdings Preference Shares (005257) | $1.67 Trillion | 10.22% | 0.94x | $2.85 Million |
| Pharmicell (005690) | $86.44 Billion | 7.32% | 0.15x | $367.60 Million |
| GeneOne Life Science Inc (011000) | $111.49 Billion | -69.75% | 0.35x | $32.81 Million |
| HLB Co. Ltd (028300) | $88.75 Billion | -14.89% | 1.10x | $3.02 Billion |
| Mgenplus Co. Ltd. (032790) | $18.79 Billion | 0.00% | 1.65x | $19.98 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $13.93 Million |
| Seoulin Bioscience Co.Ltd (038070) | $45.30 Billion | 4.03% | 0.46x | $21.44 Million |
| Hyundai Bioscience Co. Ltd (048410) | $60.94 Billion | 0.00% | 2.69x | $356.42 Million |
About Qurient Co. Ltd
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as … Read more